Alternatively, combinatorial regimens involving pharmacological myostatin inhibitors with exercise or drugs that amplify the mechanical and/or metabolic signal associated with exercise, or alternatively, gene delivery or exon skipping therapeutics designed to re-establish some degree of dystrophin protein expression back into dystrophic muscles [130,131], could bring together the benefits of both treatments to produce better translational outcomes for DMD patients. Here, DMD is linked to Duchenne muscular dystrophy.